Study guide

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies

Key Takeaways Explain This Topic AI

Cardiogenic shock is defined hemodynamically by a low Cardiac Index (<2.2 L/min/m²), elevated PAOP (>15-18 mmHg), elevated SVR (>1500 dyn·s·cm⁻⁵), and reduced Cardiac Power Output (<0.6 W).

The SCAI Shock Classification stratifies patient acuity from Stage A (At risk) to Stage E (Extremis), guiding timely escalation of vasopressors, inotropes, and percutaneous mechanical circulatory support.

Acute myocardial infarction causing >40% LV necrosis is the leading etiology, but acute mechanical complications (mitral regurgitation, VSD, free wall rupture) must be evaluated rapidly via echocardiography.

Norepinephrine is the preferred initial vasopressor for restoring MAP, while Dobutamine or Milrinone provide inotropic support; early mechanical circulatory support (Impella, VA-ECMO) should be initiated before multi-organ failure ensues.

Hemodynamic management of the 'Cold and Wet' patient requires balancing afterload reduction, inotropic contractility support, and cautious decongestion with loop diuretics.

Last updated: August 2026

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies

Cardiogenic shock (CS) is a state of severe end-organ hypoperfusion resulting from primary cardiac dysfunction. Despite advances in percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS), cardiogenic shock carries a 30-day mortality rate approaching 40% to 50%. For the AACN CMC certification exam, nurses must master hemodynamic calculations, SCAI shock staging, vasoactive titration strategies, mechanical complication identification, and MCS escalation pathways.

Pathophysiologic Spiral of Cardiogenic Shock

The fundamental defect in cardiogenic shock is severe impairment of myocardial contractility, resulting in a reduced stroke volume (SV) and cardiac output (CO). This triggers a deleterious neurohormonal compensatory cascade:

Myocardial Insult : Loss of functional myocardium (most commonly >40% of left ventricular mass during acute myocardial infarction) leads to elevated left ventricular end-diastolic pressure (LVEDP) and decreased CO.

Compensatory Neurohormonal Activation : Hypoperfusion triggers sympathetic nervous system (SNS) activation and renin-angiotensin-aldosterone system (RAAS) stimulation.

Systemic Vasoconstriction : Endogenous catecholamines, angiotensin II, and vasopressin markedly increase Systemic Vascular Resistance (SVR) to preserve Mean Arterial Pressure (MAP).

Increased Myocardial Oxygen Demand : Elevated afterload (SVR) and wall stress (LVEDP) increase myocardial oxygen consumption (MVO₂), further worsening myocardial ischemia in non-infarcted and stunned cardiac tissue.

Pulmonary & Systemic Congestion : Elevated LVEDP retrogrades into the left atrium and pulmonary venous circulation, resulting in pulmonary capillary hydrostatic pressure exceeding plasma oncotic pressure (>18-20 mmHg), causing acute hydrostatic pulmonary edema and hypoxemia.

Invasive Hemodynamic Profiling & Diagnostic Metrics

Definitive diagnosis and continuous monitoring of cardiogenic shock rely on invasive hemodynamic monitoring via Pulmonary Artery Catheterization (PAC) and arterial lines.

  • Hemodynamic Parameter Standard Reference Range Cardiogenic Shock Profile Clinical Significance & Calculation
  • Cardiac Output (CO) 4.0 – 8.0 L/min < 4.0 L/min CO = HR × SV; total volume pumped per minute

Cardiac Index (CI) 2.5 – 4.0 L/min/m² < 2.2 L/min/m² (or <1.8 without support) CI = CO / BSA; indexed to body surface area

Pulmonary Artery Occlusion Pressure (PAOP) 8 – 12 mmHg > 15 – 18 mmHg Reflects LVEDP and left heart filling pressure

Systemic Vascular Resistance (SVR) 800 – 1200 dynes·sec/cm⁵ > 1500 dynes·sec/cm⁵ SVR = [(MAP - CVP) / CO] × 80; reflects LV afterload

Central Venous Pressure (CVP) 2 – 6 mmHg > 10 – 15 mmHg Reflects right atrial pressure and right heart volume

Cardiac Power Output (CPO) 0.7 – 1.1 Watts < 0.6 Watts CPO = (MAP × CO) / 451; strongest hemodynamic mortality predictor

Pulmonary Artery Pulsatility Index (PAPi) > 2.0 < 0.9 – 1.0 PAPi = (PASP - PADP) / CVP; sensitive indicator of RV failure

  • Mixed Venous O₂ Saturation (SvO₂) 65% – 75% < 60% Decreased due to high tissue oxygen extraction ratio
  • Cardiac Power Output (CPO) & PAPi Calculations

Cardiac Power Output (CPO) : CPO is calculated as MAP × CO/451. A resting CPO below 0.6 Watts despite initial pharmacological intervention indicates severe catastrophic pump failure and is the primary hemodynamic threshold for escalating to percutaneous mechanical circulatory support.

Pulmonary Artery Pulsatility Index (PAPi) : Calculated as PASP - PADP/CVP. A PAPi value below 0.9 in the setting of acute inferior MI or left ventricular assist device (LVAD) evaluation strongly indicates acute Right Ventricular (RV) failure.

SCAI Shock Classification & Acuity Staging

The Society for Cardiovascular Angiography and Interventions (SCAI) established a standardized 5-stage shock classification system to guide clinical evaluation and escalation of care.

SCAI Stage Name Hemodynamic & Clinical Features Lactate & Perfusion Markers Recommended Management

Stage A At Risk Normal hemodynamics (CI >2.5, PAOP normal), no clinical hypoperfusion; large acute MI, acute myocarditis, or acute HF exacerbation. Normal lactate (<2.0 mmol/L), normal renal/liver function. Close telemetry/ICU monitoring, guideline-directed medical therapy.

Stage B Beginning Sinus tachycardia, narrow pulse pressure, mild hypotension (SBP <90 mmHg or MAP <65 mmHg) without clinical hypoperfusion. Normal lactate (<2.0 mmol/L), preserved urine output (>0.5 mL/kg/h). Volume trial if PAOP low, modest vasopressor initiation if hypotensive.

Stage C Classic Hypoperfusion requiring vasoactive infusions or mechanical support to maintain systemic perfusion; CI <2.2, PAOP >15. Elevated lactate (>2.0–4.0 mmol/L), oliguria, cool extremities, altered mental status. Invasive PAC monitoring, combination vasopressor/inotrope infusion, early MCS evaluation.

Stage D Deteriorating Failure of initial interventions (vasopressors/inotropes) to restore stability after 30–60 minutes; escalating drug requirements. Rising lactate (>4.0 mmol/L), worsening metabolic acidosis, progressive renal/hepatic injury. Rapid escalation to percutaneous MCS (Impella, VA-ECMO), multidisciplinary shock team activation.

Stage E Extremis Refractory cardiac arrest, ongoing CPR, severe combined metabolic/lactic acidosis, circulatory collapse. Lactate >8.0–10.0 mmol/L, pH <7.15, multi-organ breakdown. E-CPR, emergent VA-ECMO cannulation, salvage advanced mechanical support.

Clinical Etiologies & Acute Mechanical Complications of AMI

While acute myocardial infarction (AMI) accounts for ~80% of cardiogenic shock cases, critical care nurses must differentiate primary LV muscular failure from acute mechanical complications of AMI, which present with sudden hemodynamic collapse typically 2 to 7 days post-infarction.

Acute Mechanical Complications of AMI

Acute Papillary Muscle Rupture (Acute Mitral Regurgitation) :

Mechanism : Necrosis of the posteromedial papillary muscle (single blood supply from the Posterior Descending Artery / RCA). Causes catastrophic holosystolic regurgitation into a non-compliant left atrium.

Clinical Signs : Sudden pulmonary edema, new harsh holosystolic murmur at apex radiating to axilla, giant v-waves on PAOP waveform tracing.

Management : Immediate IV Nitroprusside (if SBP permits) or IABP for afterload reduction, urgent surgical valve repair/replacement.

Ventricular Septal Defect (VSD) :

Mechanism : Transmural necrosis of the anterior or inferior septum creating a left-to-right shunt.

Clinical Signs : Harsh, loud holosystolic murmur at left lower sternal border with a palpable thrill; oxygen saturation step-up ≥ 10% between the Right Atrium (RA) and Right Ventricle (RV) / Pulmonary Artery (PA).

Management : Emergency IABP or Impella placement, urgent surgical or percutaneous closure.

Free Wall Rupture :

Mechanism : Full-thickness myocardial tear leading to rapid hemopericardium and cardiac tamponade.

Clinical Signs : Sudden electromechanical dissociation (PEA), Beck's triad (hypotension, JVD, muffled heart sounds), pulsus paradoxus.

Management : Immediate bedside pericardiocentesis and emergency open thoracotomy.

Pharmacological Vasoactive Management

Vasopressors and inotropes are essential for stabilization but must be titrated cautiously to avoid excessive myocardial oxygen consumption (MVO₂) and arrhythmogenesis.

Agent Primary Receptor Activity Hemodynamic Effects Dosing Guidelines Clinical Indications & Considerations

Norepinephrine α₁ > beta₁ ↑↑ MAP, ↑ SVR, modest ↑ CO Initial: 0.02 – 0.05 mcg/kg/min; Titrate to MAP ≥ 65 mmHg First-line vasopressor in CS; less arrhythmogenic and less tachycardia than dopamine.

Dobutamine beta₁ > beta₂ > α₁ ↑↑ CO/CI, ↓ PAOP, ↓ SVR (inodilator) Initial: 2.5 – 5.0 mcg/kg/min; Range: 2.5 – 20 mcg/kg/min First-line inotrope for low CI with adequate MAP; causes tachycardia and ventricular ectopy.

Milrinone PDE-3 inhibitor ↑↑ CO/CI, ↓↓ SVR, ↓↓ PVR (inodilator) Initial: 0.125 – 0.25 mcg/kg/min (no bolus in shock) Ideal for pulmonary hypertension or concomitant RV failure; renal clearance (dose reduce in AKI).

Epinephrine beta₁ = beta₂ > α₁ (low dose); α₁ > beta₁ (high dose) ↑↑ MAP, ↑↑ CO, ↑ SVR Initial: 0.01 – 0.05 mcg/kg/min; Titrate up to 0.5 mcg/kg/min Second-line agent for refractory shock; causes hyperlactatemic metabolic acidosis and marked tachycardia.

Vasopressin V₁ₐ receptors ↑↑ SVR, ↑ MAP, no change in HR/CO Fixed dose: 0.03 units/min (do not titrate) Adjunctive non-adrenergic vasopressor for vasoplegic shock; does not increase pulmonary vascular resistance.

Mechanical Circulatory Support (MCS) Escalation Timing

When vasopressors and inotropes fail to achieve a CI > 2.2 L/min/m² or CPO > 0.6 W, percutaneous MCS must be deployed rapidly. CARDIOGENIC SHOCK PROFILE

  • (CI <2.2, PAOP >15-18, CPO <0.6W, MAP <65)
  • │
  • ▼
  • ┌─────────────────────────────────────┐
  • │ Initial Pharmacotherapy & PAC Setup │
  • │ Norepinephrine + Dobutamine/Milrinone│
  • └──────────────────┬──────────────────┘
  • │

Is Patient Stabilized?

  • (CI >2.2, Lactate Down)
  • │ │
  • YES ───────┘ └─────── NO (SCAI C/D/E)
  • │ │
  • ▼ ▼
  • Continue Titration Select Percutaneous MCS
  • De-escalate Drips │
  • ├──────────────────────────┐
  • ▼ ▼
  • Isolated LV Failure Severe Biventricular /
  • (Impella CP / 5.5) Pulmonary Collapse
  • │ (VA-ECMO ± Impella)
  • ▼ │
  • Direct LV Unloading ▼
  • ↓LVEDP, ↓MVO2, ↑CO Full Biventricular &
  • Gas Exchange Support
  • Comparison of Mechanical Support Devices

Intra-Aortic Balloon Pump (IABP) : Positioned in descending thoracic aorta distal to left subclavian artery. Diastolic inflation increases coronary artery perfusion pressure; systolic deflation reduces LV afterload and stroke work. Provides modest CO increase (~0.5 L/min). Contraindicated in Aortic Regurgitation and Aortic Dissection.

Impella (2.5, CP, 5.0, 5.5) : Catheter-based microaxial flow pump positioned across aortic valve. Draws blood directly from LV and expels into ascending aorta. Delivers 2.5 to 5.5 L/min continuous flow, actively unloading the LV, reducing wall stress and PAOP, and dramatically decreasing MVO₂.

Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) : Cannulated via femoral vein (drainage) and femoral artery (reinfusion). Provides 5 to 7 L/min full biventricular and pulmonary oxygenation support. Key Drawback : Increased retrograde aortic blood flow increases LV afterload and LVEDP, potentially worsening pulmonary edema. Co-administration of an Impella with VA-ECMO ( ECPELLA ) is increasingly utilized to achieve LV venting.

Loading diagram... SCAI Shock Staging & Hemodynamic Escalation Algorithm